[1]韩艳,邓华英,吴春雷,等.中西医联合用药与钙尔奇D单药治疗对绝经后骨质疏松疗效的观察[J].中医正骨,2011,23(11):17-19.
　HAN Yan*,DENG Hua-ying,WU Chun-lei,et al.Therapeutic effect of combined use of traditional Chinese medicine and Western medicine or caltrate D alone in postmenopausal osteoporosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2011,23(11):17-19.
点击复制

中西医联合用药与钙尔奇D单药治疗对绝经后骨质疏松 疗效的观察()
分享到：

《中医正骨》[ISSN:1001-6015/CN:41-1162/R]

卷:
第23卷
期数:
2011年11期
页码:
17-19
栏目:
临床研究
出版日期:
2011-11-30

文章信息/Info

Title:
Therapeutic effect of combined use of traditional Chinese medicine and Western medicine or caltrate D alone in postmenopausal osteoporosis
作者:
韩艳; 邓华英; 吴春雷; 吴云刚; 吴剑静
温州医学院附属第一医院,浙江 温州 325000
Author(s):
HAN Yan*; DENG Hua-ying; WU Chun-lei; et al.*
No.1 Hospital Affiliated to Wenzhou Medical College,Wenzhou 325000,Zhejiang,China
关键词:
骨质疏松 补肾活血方 阿仑膦酸钠 钙尔奇D 骨密度
Keywords:
Osteoporosis; Bushenhuoxue prescription; Alendronate; Cahrate; Bone mineral density
摘要:
目的:观察中药补肾活血方联合阿仑膦酸钠(ALN)、钙尔奇D综合治疗与单纯钙尔奇D治疗绝经后骨质疏松症的骨密度变化。方法:绝经后骨质疏松患者70例,随机分为:综合治疗组35例,给予补肾活血方(每天1剂)、ALN(每周70 mg)和钙尔奇D(每天600 mg); 钙尔奇D组35例(每天600 mg),总疗程6个月。采用双能X线骨密度测量仪(DXA)测定治疗前后腰椎、股骨颈及Wards三角骨密度。结果:70例患者全部进入结果分析。两组治疗后各部位骨密度均有增加。但中药补肾活血方联合ALN、钙尔奇D综合治疗组比单纯钙尔奇D组骨密度增加更为显著,差异有统计学意义(P<0.05); 不良反应ALN主要为上腹部不适,钙尔奇D则以便秘为主。结论:中药补肾活血方联合ALN、钙尔奇D综合治疗可以明显提高绝经后骨质疏松患者的骨密度,缓解患者疼痛,并具有良好的耐受性和安全性。
Abstract:
Objective:To compare changes in bone mineral density(BMD)after 6 months use of traditional Chinese medicine and Western medicine versus Cahrate D alone in postmenopausal osteoporosis.Methods:70 of postmenopausal osteoporosis were randomly assigned to either combined use of traditional Chinese medicine and Western medicine(Bushenhuoxue prescription,70 mg·week-1 ALN and 600 mg·day-1 Caltrate D)or Cahrate D group for 6 months.BMD at lumbar spine, collum femoris and wards triangle was measured by dual-energy X-ray absorptiometry(DEXA)before and after the treatment.Results:All 70 patients were included in the final analysis.BMD increased at each region in both groups.The BMD at lumbar spine,collum femoris and wards triangle in treatment group with Bushenhuoxue prescription,ALN and Caltrate D increased more that in the group of Caltrate D alone.There was statistical difference between the 2 groups(P<0.05).The main adverse reactions:upper abdominal discomfort of ALN and constipation of Cahrate D.Conclusion:Comprehensive treatment group with Bushenhuoxue prescription,ALN and Caltrate D increase BMD significantly in postmenopausal osteoporosis.And it is safe,generally well tolerated and efficient in pain relief as a treatment for postmenopausal osteoporosis.

参考文献/References:

[1] 刘忠厚.中国人骨质疏松症的建议诊断标准(2稿)[J].中国骨质疏松杂志,2000,6(1):2.
[2] 高小明,常虹,李紫英.绝经后骨质疏松症的中医病因病机的研究进展[J].内蒙古中医药,2006,25(5):60-62.
[3] 陈明,郑琼,方真华,等.阿伦膦酸钠对骨髓生成破骨细胞及骨吸收作用的影响[J].中国矫形外科杂志,2008,16(4):282-284.
[4] Takada J,Iba K,Imoto K,et al,changes in bone resorption markers among Japanese patients with postmenopausal osteoporosis treated with alendronate and risedronate[J].J Bone Miner Metab,2007,25(2):142-146.
[5] 邓丽丽,陈海翎,李明升.阿伦膦酸钠治疗绝经后骨质疏松症100例分析[J].中国骨质疏松杂志,2010,16(2):132-135.
[6] Schacht E,Dukas L,Richy F.Combined therapies in osteoporosis:bisphosphonates and vitamin D-hormone analogs[J].J Musculoskelet Neuronal Interact,2007,7(2):174.
[7] Chapurlat RD,Palermo L,Ramsay P,et al.Risk of fracture among women who lose bone density during treatment with alendronate.The Fracture Intervention tria1[J].Osteoporos Int,2005,16(7):842-848.
[8] North American Menopause Society.Management of osteoporosisin in postmenopausal women:2006 position statement of the North American Menopause Society[J].Menopause,2006,13(3):340-367.
[9] 孟迅吾,朱汉民,刘建立,等.阿仑膦酸钠治疗绝经后骨质疏松症的疗效与耐受性[J].基础医学与临床,2007,27(2):201-204.

更新日期/Last Update: 1900-01-01